Enhancing melanoma therapy with hydrogel microneedles DOI Creative Commons
Leilei Zhu,

Ge Qiao,

Hongwei Gao

et al.

Frontiers in Oncology, Journal Year: 2025, Volume and Issue: 15

Published: April 17, 2025

Melanoma is highly invasive and resistant to conventional treatments, accounting for nearly 75% of skin cancer-related deaths globally. Traditional therapies, such as chemotherapy immunotherapy, often exhibit limited efficacy are associated with significant side effects due systemic drug exposure. Microneedles (MNs), an emerging delivery system, offer multiple advantages, including safety, painlessness, minimal invasiveness, controlled release. Among these, hydrogel microneedles (HMNs) stand out their extracellular matrix-like structure swelling-induced continuous channels, which enable the direct therapeutic agents into tumor microenvironment (TME). This approach enhances bioavailability while reducing toxicity, establishing HMNs a promising platform melanoma treatment. review highlights recent advancements in therapy, focusing on applications biomarker extraction early diagnosis role supporting multimodal treatment strategies, chemotherapy, phototherapy, targeted combination therapy. Furthermore, current matrix materials fabrication techniques discussed. Finally, limitations critically analyzed, recommendations future research development provided.

Language: Английский

DCVax-L Vaccination in Patients with Glioblastoma: Real Promise or Negative Trial? The Debate Is Open DOI Open Access
Lidia Gatto, Vincenzo Di Nunno,

Alicia Tosoni

et al.

Cancers, Journal Year: 2023, Volume and Issue: 15(12), P. 3251 - 3251

Published: June 20, 2023

The lack of significant improvement in the prognosis patients with GB over last decades highlights need for innovative treatments aimed at fighting this malignancy and increasing survival outcomes. results phase III clinical trial DCVax-L (autologous tumor lysate-loaded dendritic cell vaccination), which has been shown to increase both median long-term newly diagnosed relapsed glioblastoma, have enthusiastically received by scientific community. However, study deserves some reflections regarding methodological issues related primary endpoint change, long accrual period, suboptimal validity external control population used as comparison arm.

Language: Английский

Citations

14
Update on immune‐based therapy strategies targeting cancer stem cells DOI Creative Commons

Amirhossein Izadpanah,

Niloufar Mohammadkhani,

Mina Masoudnia

et al.

Cancer Medicine, Journal Year: 2023, Volume and Issue: 12(18), P. 18960 - 18980

Published: Sept. 1, 2023

Abstract Accumulating data reveals that tumors possess a specialized subset of cancer cells named stem (CSCs), responsible for metastasis and recurrence malignancies, with various properties such as self‐renewal, heterogenicity, capacity drug resistance. Some signaling pathways or processes like Notch, epithelial to mesenchymal transition (EMT), Hedgehog (Hh), Wnt, well CSCs' surface markers CD44, CD123, CD133, cell adhesion molecule (EpCAM) have pivotal roles in acquiring CSCs properties. Therefore, targeting CSC‐related might effectively eradicate pave the way survival. Since current treatments chemotherapy radiation therapy cannot all tumor relapse may happen following temporary recovery, improving novel more efficient therapeutic options combine is required. Immunotherapy strategies are new modalities promising results CSCs. Here, we review by immunotherapy dendritic (DC) vaccines, chimeric antigen receptors (CAR)‐engineered immune cells, natural killer‐cell (NK‐cell) therapy, monoclonal antibodies (mAbs), checkpoint inhibitors, use oncolytic viruses (OVs) pre‐clinical clinical studies. This will mainly focus on blood malignancies but also describe solid cancers.

Language: Английский

Citations

13
Recent Progress in Cancer Vaccines and Nanovaccines DOI
Kishwor Poudel,

Tulasi Vithiananthan,

Jong Oh Kim

et al.

Biomaterials, Journal Year: 2024, Volume and Issue: 314, P. 122856 - 122856

Published: Sept. 28, 2024

Language: Английский

Citations

4
Injecting hope: the potential of intratumoral immunotherapy for locally advanced and metastatic cancer DOI Creative Commons
Markéta Skaličková, Katerina Hadrava Vanova, Ondřej Uher

et al.

Frontiers in Immunology, Journal Year: 2025, Volume and Issue: 15

Published: Jan. 9, 2025

Despite enormous progress, advanced cancers are still one of the most serious medical problems in current society. Although various agents and therapeutic strategies with anticancer activity known used, they often fail to achieve satisfactory long-term patient outcomes survival. Recently, immunotherapy has shown success patients by harnessing important interactions between immune system cancer. However, many these therapies lead frequent side effects when administered systemically, prompting treatment modifications or discontinuation or, severe cases, fatalities. New approaches like intratumoral immunotherapy, characterized reduced effects, cost, systemic toxicity, offer promising prospects for future applications clinical oncology. In context locally metastatic cancer, combining diverse immunotherapeutic other targeting multiple cancer hallmarks appears crucial. Such combination hold promise improving survival promoting a sustained response. This review aims provide overview approaches, specifically focusing on administration drugs cancers. It also explores integration modalities maximize Additionally, summarizes recent advances discusses novel outlining directions field.

Language: Английский

Citations

0
Clinical development complexity of TGF-β inhibition: From fibrosis to cancer immunotherapy DOI
Gabriel Gallo-Oller,

María Isabel Guillén-Antonini,

Javier Dotor

et al.

International review of cell and molecular biology, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 1, 2025

Language: Английский

Citations

0
Cancer Vaccines and Beyond: The Transformative Role of Nanotechnology in Immunotherapy DOI Creative Commons

Violeta Delgado-Almenta,

José L. Blaya-Cánovas, Jesús Calahorra

et al.

Pharmaceutics, Journal Year: 2025, Volume and Issue: 17(2), P. 216 - 216

Published: Feb. 7, 2025

Cancer is one of the leading causes morbidity and mortality globally, responsible for approximately 10 million deaths in 2022 an estimated 21 new cases 2024. Traditional cancer treatments such as surgery, radiation therapy, chemotherapy often present limitations efficacy side effects. However, immunotherapeutic vaccines have emerged a promising approach, leveraging body’s immune system to target eliminate cells. This review examines evolving landscape vaccines, differentiating between preventive therapeutic strategies highlighting significance tumor-specific antigens, including tumor-associated antigens (TAAs) neoantigens. Recent advancements vaccine technology, particularly through nanotechnology, resulted development nanovaccines, which enhance antigen stability, optimize delivery cells, promote robust responses. Notably, clinical data indicate that patients receiving checkpoint inhibitors can achieve overall survival rates 34.8 months compared just 15.7 traditional therapies. Despite these advancements, challenges remain, immunosuppressive tumor microenvironment heterogeneity. Emerging evidence suggests combining nanovaccines with immunomodulators may by overcoming obstacles. Continued research interdisciplinary collaboration will be essential fully exploit promise ultimately more effective accessible patients. The future immunotherapy appears increasingly hopeful innovative pave way enhanced patient outcomes improved quality life oncology.

Language: Английский

Citations

0
Revolutionizing cancer treatment: The power of dendritic cell-based vaccines in immunotherapy DOI Open Access
Mohsen Sheykhhasan, Amirhossein Ahmadieh-Yazdi, Reza Heidari

et al.

Biomedicine & Pharmacotherapy, Journal Year: 2025, Volume and Issue: 184, P. 117858 - 117858

Published: Feb. 16, 2025

Language: Английский

Citations

0
Dendritic Cell-Based Glioblastoma Vaccines: Advances and Challenges DOI Creative Commons
Zuowen Zhang, Mingchang Li, Jie Huang

et al.

IntechOpen eBooks, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 14, 2025

Glioblastoma (GBM) is the most aggressive malignancy of central nervous system. Despite advances in standard treatments such as surgery, radiotherapy, and chemotherapy, patients have a very poor prognosis. Tumor vaccines based on dendritic cells (DCs) provide promising new approach for GBM treatment. DCs, effective antigen-presenting cells, initiate adaptive immune responses by activating tumor-specific T cells. However, immunosuppressive microenvironment (characterized regulatory myeloid suppressor factors) physical barrier blood-brain (BBB) greatly limit efficacy DC vaccines. This chapter explores biological basis, preparation process, clinical progress, challenges, future directions DC-based Key aspects antigen selection, vitro culture activation, loading, delivery strategies are analyzed detail. Early trials demonstrated safety potential vaccines, while combination therapies reprogramming being used to overcome existing obstacles. precision personalization highlight their focus immunotherapy research. We believe that with continuous advancement technology interdisciplinary collaboration, can significantly improve survival rate quality life patients.

Language: Английский

Citations

0
The paths toward immunotherapy of esophageal cancer: An overview of clinical trials DOI
Azfar Jamal,

Allolo D Aldreiwish,

Saeed Banawas

et al.

International Immunopharmacology, Journal Year: 2025, Volume and Issue: 151, P. 114261 - 114261

Published: Feb. 26, 2025

Language: Английский

Citations

0
Oncogenic and Immunological Roles of FRS2 and its Potential Value in Retroperitoneal Liposarcoma: from Bioinformatics Analysis to Clinicopathological Evidence DOI Creative Commons
Hao Yu, Shuquan Li, Yifan Wu

et al.

International Journal of Medical Sciences, Journal Year: 2025, Volume and Issue: 22(8), P. 1825 - 1836

Published: March 10, 2025

Background: Retroperitoneal liposarcoma (RLPS) is a rare malignancy with no effective treatment beyond surgical intervention. Identifying novel therapeutic targets and prognostic markers critical to improving outcomes. Fibroblast growth factor receptor substrate 2 (FRS2), located near MDM2 on chromosome 12q13-15, has biological role value in liposarcoma, which remain be fully explored. Methods: Bioinformatics tools were used analyze the differential expression of FRS2 across various malignancies using public databases, such as GTEx, TCGA, cBioPortal. In sarcomas (SARC), clinicopathological features, outcomes, co-expressed genes, levels tumor-infiltrating immune cells, immunostimulators, major histocompatibility complex (MHC) molecules, immunochemokines extracted from multiple databases. Tumor specimens 82 RLPS patients at our sarcoma center collected, was assessed through immunohistochemistry. Results: found upregulated amplified most cancers. GEPIA analysis showed significant variation mRNA cancer types, especially (SARC). Lower SARC correlated improved overall survival (OS) disease-free (DFS). may affect tumor microenvironment, inhibiting cell infiltration promoting evasion. cohort, overexpression observed 58.53% (48/82) cases age (P = 0.009). High associated poorer OS DFS 0.049 P < 0.001, respectively), multivariate confirmed an independent factor. Conclusion: serve potential biomarker oncogene target. Additionally, could play represents promising immunotherapeutic target for treatment.

Language: Английский

Citations

0